Theravance Biopharma Inc (NASDAQ:TBPH) EVP Bradford J. Shafer sold 7,119 shares of the business’s stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $27.71, for a total transaction of $197,267.49. Following the transaction, the executive vice president now owns 84,000 shares in the company, valued at $2,327,640. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of TBPH stock opened at $28.84 on Friday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of -5.29 and a beta of 1.80. The company has a debt-to-equity ratio of 6.52, a quick ratio of 3.95 and a current ratio of 4.14. Theravance Biopharma Inc has a 52 week low of $21.27 and a 52 week high of $35.90.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.44. The business had revenue of $23.48 million for the quarter, compared to analyst estimates of $9.97 million. Theravance Biopharma had a negative net margin of 640.07% and a negative return on equity of 261.70%. research analysts predict that Theravance Biopharma Inc will post -4.41 earnings per share for the current year.

Several research firms recently weighed in on TBPH. BidaskClub upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Friday, May 11th. Needham & Company LLC restated a “buy” rating and set a $40.00 price target on shares of Theravance Biopharma in a report on Wednesday, May 9th. Cantor Fitzgerald set a $55.00 price target on shares of Theravance Biopharma and gave the stock a “buy” rating in a report on Thursday, May 24th. Finally, ValuEngine upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Thursday, May 31st. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $40.00.

A number of hedge funds have recently made changes to their positions in TBPH. UBS Group AG raised its position in Theravance Biopharma by 88.4% in the first quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 2,117 shares during the period. SG Americas Securities LLC bought a new stake in Theravance Biopharma in the first quarter worth about $130,000. Xact Kapitalforvaltning AB bought a new stake in Theravance Biopharma in the first quarter worth about $202,000. Royal Bank of Canada raised its position in Theravance Biopharma by 22.3% in the first quarter. Royal Bank of Canada now owns 16,664 shares of the biopharmaceutical company’s stock worth $404,000 after acquiring an additional 3,042 shares during the period. Finally, Millennium Management LLC bought a new stake in Theravance Biopharma in the fourth quarter worth about $419,000. 85.78% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

See Also: Return on Investment (ROI) Defined, Explained

Insider Buying and Selling by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.